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Abstract
The identification of alternatively spliced transcript variants specific to particular biological processes in tumours should
increase our understanding of cancer. Hypoxia is an important factor in cancer biology, and associated splice variants may
present new markers to help with planning treatment. A method was developed to analyse alternative splicing in exon array
data, using probeset multiplicity to identify genes with changes in expression across their loci, and a combination of the
splicing index and a new metric based on the variation of reliability weighted fold changes to detect changes in the splicing
patterns. The approach was validated on a cancer/normal sample dataset in which alternative splicing events had been
confirmed using RT-PCR. We then analysed ten head and neck squamous cell carcinomas using exon arrays and identified
differentially expressed splice variants in five samples with high versus five with low levels of hypoxia-associated genes. The
analysis identified a splice variant of LAMA3 (Laminin a 3), LAMA3-A, known to be involved in tumour cell invasion and
progression. The full-length transcript of the gene (LAMA3-B) did not appear to be hypoxia-associated. The results were
confirmed using qualitative RT-PCR. In a series of 59 prospectively collected head and neck tumours, expression of LAMA3-A
had prognostic significance whereas LAMA3-B did not. This work illustrates the potential for alternatively spliced transcripts
to act as biomarkers of disease prognosis with improved specificity for particular tissues or conditions over assays which do
not discriminate between splice variants.
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Introduction
Alternative splicing is the process by which cells can selectively
include different sections of pre-mRNA during RNA processing. If
these transcripts are translated, this results in a set of closely
related, but different, proteins expressed from a single locus [1,2].
Alternative splicing is prevalent (the majority of human genes are
alternatively spliced, with an average of about 5.4 transcripts per
gene [3]), and tightly regulated. It is a key player in many
molecular pathways, and is known to be involved in many of the
‘hallmark’ processes of cancer [4], including resistance to
apoptosis, invasion, angiogenesis and differentiation [5].
Until recently, a lack of appropriate tools has made it impossible
to perform routine global surveys of alternative splicing, making it
relatively understudied. Recently, a set of exon microarrays has
been developed by Affymetrix. These feature probesets targeting
at intervals throughout each transcript, rather than simply at the
39 end interrogated by most other arrays. This enables the
assembly, in silico, of expression levels across genes providing a
more complete representation of transcription for each gene, and
allowing the identification of loci where there are changes in the
splicing pattern across experimental samples. Another useful
consequence of the increased resolution of the arrays is that since
most transcripts are targeted by multiple probesets, their signals
can be combined in order to increase statistical power [6]. This
leads to the identification of differentially expressed genes with
smaller effects sizes than can be found using other, less
comprehensive platforms. However, this increased performance
is not without additional challenges, since detailed analysis of the
arrays requires annotation describing the known relationships
between genes, transcripts and exons, and the ability to combine
this with appropriate statistics [7–9].
Here we use Affymetrix Exon 1.0ST arrays to study hypoxia in
human cancers. Hypoxia can lead to an altered, invasive tumour
phenotype through wide ranging changes in gene transcription
within a cell. Perhaps the best known mediator of this is hypoxia
PLoS Computational Biology | www.ploscompbiol.org 1 November 2009 | Volume 5 | Issue 11 | e1000571inducible factor 1a (HIF{1a), a transcription factor that regulates
the expression of many tumorigenic genes involved in a wide range
of cellular processes, including angiogenesis, cell proliferation,
apoptosis and cell migration [10]. Several well known HIF{1a
regulated (and cancer associated) genes (e.g. VEGFA [11], CA9
[12]) are already known to be alternatively spliced, although the
relationship between hypoxia, differential transcript expression,
alternative splicing, and tumour phenotype has yet to be fully
determined. Given the ubiquity of alternative splicing, it is likely
that there are many more such events to be discovered.
To date, most published metrics used to analyze alternative
splicing compute an overall gene level summary that is used as a
baseline against which the behaviour of its constituent exons can
be compared. The most popular metric is the splicing index
[2,13,14], which aims to identify probesets that have different
inclusion rates (relative to the gene level) between two sample
groups. MIDAS is an extension of the splicing index that uses
ANOVA instead of a t-test to evaluate significance, allowing
comparisons between multiple sample groups. In FIRMA [15], the
popular linear model Robust Multichip Analysis (RMA) (used for
normalization and summarization of probeset intensities) is fitted
to each gene in order to estimate overall expression level in each
sample, while the median of the residuals in an exon is used to
generate a summary statistic of each exon’s alternative splicing.
The method was developed to evaluate situations where there are
neither replicates nor pre-defined groups. MADS [16] calculates
splicing indices and p-values of individual probes separately, prior
to summarization at probeset level. The Pattern-based Correlation
(PAC) [17,18] algorithm is based on the correlation across samples
between exon expression levels and the overall gene expression
level. PAC is limited by the number of samples, since it works best
when there are enough differentially spliced samples to signifi-
cantly weaken the correlation between gene and exon. Genes,
exons or probesets scoring highly in an algorithm/metric (and
usually accompanied by a low probability score) are identified as
promising candidates of alternative splicing events and are suitable
for further tests. As discussed elsewhere [15], alternative splicing is
an analogue process, with no threshold above which alternative
splicing can be said to occur. Results are therefore usually reported
as a ranked list.
We used exon microarrays to study alternative splicing events in
hypoxia-associated genes in a set of ten Head and Neck Squamous
Cell Carcinomas (HNSCC). These samples are a subset of 59
HNSCC collected and analysed previously [19]. The 10 samples
comprised the 5 most and 5 least hypoxic samples, determined by
their Hypoxia Score (HS), a gene signature derived metric of
tumour hypoxia [19].
To identify hypoxia-associated genes, we developed a novel
approach that increases the power of detection of differentially
expressed genes by exploiting the fact that most transcripts are
targeted by multiple, independent probesets. Using this approach,
we identified 146 genes with significant hypoxia-related changes in
exon expression across their loci, the set includes a higher number
of known hypoxia-induced genes compared to the equivalent
analysis on HG-U133A Plus2 arrays. To identify alternative
splicing events we used a combination of the splicing index and a
new metric, proposed here, based on the variation of reliability
weighted fold changes (VFC). The weights are based on Detection
Above the Background (DABG) scores [20,21], which relate to the
probability that the observed probeset signal is higher than the
background noise distribution. We show here that the inclusion of
probeset reliability information improves the detection of alterna-
tive splicing events when applied not only to our hypoxia data but
also when applied to an independent dataset.
The proposed strategy identified SLCO1B3 (Organic anion-
transporting polypeptide 8 (OATP8), ENSG00000111700), WDR66
(WD repeat-containing protein 66, ENSG00000158023), COL4A6
(Collagen a{6I V ðÞ chain precursor, ENSG00000197565) and
LAMA3 (Laminin subunit a{3 precursor, ENSG0000053747) as
potentially involved in alternative splicing events related to hypoxia.
The strongest evidence was for LAMA3 which was successfully
validated by RT-PCR. We also found that expression of the
LAMA3-A splice variant in head and neck cancers was strongly
associated with poorer survival following primary surgical treat-
ment, showing that our methodology can be used to identify novel
splicing events with prognostic significance.
Results
Alternative splicing in the colon cancer dataset
In order to ensure the validity of our approach, it was applied to
the colon cancer sample dataset (10 paired normal-cancer samples)
from Affymetrix (http://www.affymetrix.com). In [2] the dataset
was analysed to identify alternative splicing events and RT-PCR
validation of 49 genes (chosen based on splicing index p-values of
filtered genes/probesets, manual inspection and literature infor-
mation) was performed. Out of these, differential AS events in
colon cancer relative to normal colon tissue were confirmed as
either present or absent in 27 genes: eleven genes showed clear
differential AS and 16 showed no evidence of AS. Of the
remaining 22 genes, 5 showed positive results but with some
ambiguity and 17 exhibited AS but were not distinctive between
normal and cancerous tissues.
The pipeline described in Materials and Methods (Figure 1) was
used to identify genes for which there were significant changes in
expression in one or more exons across their length. We refer to
these as differentially expressed (DE) genes, and do not at this stage
consider whether expression changes are uniform across their
length. We identified 1091 DE genes, 892 up-regulated in colon
cancer relative to normal colon tissue and 198 down-regulated.
We set the FDR cut-off of the paired t-test to 10% to include as
many genes validated by RT-PCR as possible. Fifteen of the 27
Author Summary
Alternative splicing is the process by which cells express a
set of different, but related, transcripts from a single gene.
When translated, each transcript results in a different
protein, resulting in additional cellular complexity. Affyme-
trix Exon microarrays, which feature multiple probesets
targeting different locations throughout each gene, allow
the changes in transcription that result from alternative
splicing to be investigated in a single genome-wide assay.
In addition, the increased number of probesets targeting
each gene offers the potential to combine signals in order
to increase statistical power, allowing smaller changes to
be detected reliably. We developed a novel algorithm to
exploit both these aspects of exon arrays and applied it to
tumour hypoxia in clinical samples. Our method identified
4 potential transcript variants upregulated in hypoxic
cancers, including a splice variant of the Laminin alpha 3
gene, which we were then able to validate by other
methods. On further investigation, we found that expres-
sion of this particular isoform in head and neck cancers
was a strong adverse prognostic factor for survival
following primary surgical treatment. This shows that
exon arrays can be used to identify clinically relevant
splicing events with potential utility as prognostic
biomarkers.
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present or absent can be found in the set of DE genes obtained.
A plot of the ranked VFC values versus the ranked splicing
indices (metrics described in Materials and Methods) of the DE
genes shows that most of the genes successfully confirmed by RT-
PCR are placed in the top ranks by VFC apart from FN1 and
SLC3A2 which are in the bottom 50% (Figure 2A). Interestingly,
SLC3A2 had also a low rank in the analysis performed in [15].
Most of the genes that did not show alternative splicing events are
given lower ranks by the VFC but not by the splicing index.
Figure 1. Analysis pipeline for the detection of genes with changes in expression across their loci (here referred to as differentially
expressed (DE) genes) in exon array data. All array probesets go through a 3 stage filtering procedure in order to detect DE probesets. First the
‘‘Probeset filter’’ selects non-multiply targeting exonic probesets with §4 probes, then the ‘‘DABG filter’’ identifies the probesets present in at least all
samples of the same group, finally the ‘‘t-test filter’’ detects probesets with a statistically-significant difference between the two groups at a 5% FDR.
The resulting DE probesets are driven through two parallel tracks. Track 1: a further filter for fold change at a 5% FDR is used. This yields DE probesets
with large fold changes. The probesets are mapped to genes, and these are labelled as DE genes from Track 1. Track 2: DE probesets are mapped to
genes. The genes are mapped back to probesets and genes with §25% of DE probesets relative to the total non-multiply targeting exonic gene’s
probesets are selected and labelled as DE genes from Track 2. Total DE genes are the combined DE genes from the two tracks.
doi:10.1371/journal.pcbi.1000571.g001
Figure 2. Alternative splicing in the Affymetrix colon cancer sample dataset. (A) Ranked splicing indices (SI) versus ranked VFC values. Light
background: true positives, dark background: false positives. (B) ROC curve.
doi:10.1371/journal.pcbi.1000571.g002
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found to have no alternative splicing event by RT-PCR validation.
The inclusion of probeset reliability information in the VFC
enables a better differentiation between the true and false positives
(Figure 2B).
Genes with hypoxia-induced changes in expression
across their loci in the head and neck dataset
While Hypoxia causes a general down- rather than up-
regulation in gene expression [22], most up-regulated genes are
HIF{1a dependent [22]. This study focused on up-regulated
changes, as they represent a more specific target group. The
pipeline described in Materials and Methods was used to identify
genes with hypoxia-induced changes in expression across their loci
(i.e. hypoxia-associated genes) in the Head and Neck dataset.
Essentially, the pipeline aims to find genes for which at least one
exon shows a big change or for which many exons show a smaller
but consistent change. The filtering stage identifies exon targeting
probesets predicted to hybridize to a single locus within the
genome, which are significantly differentially expressed between
high and low HS samples (DE probesets). The analysis then takes
place in two parallel tracks, one that identifies genes targeted by at
least one DE probeset with a significantly large change (Track 1)
and the other that seeks genes targeted by a high proportion of DE
probesets (Track 2).
Filtering procedure. There are 1,411,189 probesets on the
array that target 33,736 genes based on ENSEMBL annotations
(Version 50). Filtering out probesets with v4 probes left 667,704
probesets targeting 28,825 genes, of which 292,040 are defined as
exonic probesets. After filtering to retain probesets flagged as
present (DABGv0:01) in at least 5 samples of the same group,
149,963 remained. A t-test between groups with a cut-off at an
FDR of 5% yielded 3,749 DE probesets.
Dual track workflow. In Track 1 of the pipeline 422 DE
probesets, targeting 82 genes, had a positive FC value at a 5%
FDR. In Track 2 of the pipeline, up-regulated DE probesets
(1,4212 Pup probesets) mapped to 469 genes. These genes were
mapped to probesets and the proportion of Pup in each gene
calculated. This yielded 123 genes with a high proportion (w0:25)
of Pup. A total of 146 genes (Table S1) potentially induced under
hypoxia resulted from the union of the two tracks of the procedure.
DE genes. The final set of DE genes was mapped on to the
Gene Ontology using DAVID [23,24]. Around one quarter of
these genes are involved in processes known to be activated in
tumours under hypoxia conditions [10] (e.g. cell proliferation,
glycolysis, angiogenesis, cell motility and cell migration), see
Table 1. This further validates the hypoxia score derived in [19] as
a method of stratifying hypoxia in head and neck cancers.
The list of DE genes includes 24 genes of the 99 HS genes (see
Head and Neck Cancer dataset in Materials and Methods), 1
exclusively from Track 1, 14 from both tracks and 9 from Track 2
of the pipeline, highlighting the importance of Track 2. Table 2
shows the intersection between both tracks with the HS genes, and
with genes previously reported in the literature to be hypoxia
induced [19]. We followed an equivalent procedure to identify DE
genes in the same samples arrayed in the HG-U133A Plus2 chips.
We used a t-test at 5% FDR on non-multiply targeting probesets
that passed the mismatch score filtering (equivalent to DABG
score filtering). We obtained a total of 64 DE genes which include
12 of the 99 HS genes (Table 2). It is important to note that none
of the HS/Lit genes identified by the second track are found using
the HG-U133A Plus2 arrays.
Probesets containing a single ‘‘outlier sample’’ tend to be
rejected as DE more often in the exon arrays than in the HG-
U133A Plus2 arrays because the mean difference between the high
and low HS samples tends to be smaller on exon arrays (see, for
example, SLC38A5 and HSD17B1 in Figure S1). This shift of low
Table 1. Hypoxia associated genes.
ABC D EF G H
SLC2A1 SLC3A2 IL1A HTR7 YKT6 CDH13 ALDOA CDH13
SLCO1B3 SLC16A1 TGFA NRG1 TUBB6 S100A2 LDHA ACTN1
SLC7A8 CAV2 CAV1 CAP2 HK2 LAMA3
SLC7A5 KCTD11 CAV2 CAV2
FOSL1 ACTN1
BNC1 TUBA1C
CDH13 PFN2
TCFL5 PLS3
CAV1
IGFBP6
PTHLH
IMPDH1
MET
NUMB
Genes identified as potentially induced under hypoxia that belong to processes
known to be activated in tumours under hypoxia conditions. A=Anion
transport, B=Carboxylic acid transport, C=Cell proliferation, D=Circulatory
system process, E=Cytoskeleton organization and biogenesis, F=Endothelial
cell migration, G=Glycolysis, H=Regulation of cell motility.
doi:10.1371/journal.pcbi.1000571.t001
Table 2. Hypoxia associated genes identified by exon and
39IVT arrays.
Exon data T1 Exon data T1 & T2 Exon data T2 39IVT data
HS genes IGF2BP2 NDUFA4L2 AC133461.4 NDUFA4L2
PYGL CORO1C PYGL
SLCO1B3 CNIH4 SLCO1B3
HOMER1 KCTD11 AK3L2
KRT17 TPD52L2 S100A3
TANC2 ALC6A10P
HS and Lit
genes
CA9 ALDOA CA9
CA12 LDHA CA12
SLC2A1 NDRG1 SLC2A1
SLC16A1 SLC16A1
SLC6A8
BNIP3
Lit genes F3 SLC3A2 F3
TGFA TGFA
HK2
MET
Genes identified as potentially induced under hypoxia, using exon and 39IVT
arrays, which are members of the HS genes and/or genes known to be
h y p o x i ai n d u c e di nt h el i t e r a t u r e( L i tg e n e s ) .T h eg e n e sa r es o r tb yt h e
pipeline track (Track 1 (T1)a n dT r a c k2( T2)) and array platform which
identified them and their membership to the set of HS genes and the set of
Lit genes.
doi:10.1371/journal.pcbi.1000571.t002
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expression level in the exon array and the shift of high expression
signal from U133 Plus2 to a relatively lower expression level in the
exon array, has been identified before [2]. On the other hand,
many probesets are lost to cross-hybridization in the HG-U133A
Plus2 arrays, and there are not enough probesets per gene to
consider the proportion of low but significant fold changes as a
means to identify DE genes. Figure S2 shows the exon array data
for ALDOA, an example of a known hypoxia-induced gene
detected only by making use of the probeset multiplicity (Track
2) available in exon arrays.
Alternative splicing in the HNSCC dataset
A combination of the splicing index and the VFC identified
alternative splicing events in hypoxia-associated genes. Figure 3
plots the ranked splicing indices versus the ranked VFC values,
before and after the inclusion of the DABG information. Six genes
(PYGL, BNC1, HMGA2, SLCO1B3, SNAI2 and CA12) show a high
splicing index rank but low VFC rank. On further inspection, all of
these have one or two probesets found to be absent in all samples,
with low fold change (e.g. Figure 4A). This could indicate an
alternative splicing event that is not correlated with hypoxia. We
found that in five of the six genes these absent probesets were
consistently absent in all replicates of the tissue panel sample data-
set from Affymetrix (available at http://www.affymetrix.com/),
suggesting that the absent probesets are very likely to be poorly
performing probesets. An alternative splicing event was therefore
considered unlikely, and these genes to be false positives. In the
case of SLCO1B3, the three replicates of liver are present and
highly expressed across all probesets, showing that the probeset
absent in HNSCC is not faulty (Figure 4B). SLCO1B3 has two
known transcripts (Figure S3) and the information provided by the
arrays indicates that samples with high HS express only the shorter
transcript of SLCO1B3, while in liver the longer transcript is
expressed. However, nothing can be inferred from the low HS
samples because most probesets are absent in these samples. The
gene in the left-top of Figure 3B (DVL1) is ranked high by VFC
and low by splicing index. Manual comparison to the Affymetrix
sample dataset, revealed that most of the FC variation is due to
probesets with a low range of response.
Genes with high ranks on both metrics (SI and VFC) are likely to
be alternative spliced. Fivegenesremained at the top of the ranking of
both metrics (top 0.5 quantile of the combined ranking (SI+ VFC))
after inclusion of the DABG information (LAMA3, WDR66, NRG1,
NDUFA4L2 and COL4A6). LAMA3 is targeted by a large number of
probesets, generally present across samples. Detailed examination
shows that one of its three known transcripts (ENST00000269217
LAMA3-A) is differentially expressed in response to hypoxia, while
the other two transcripts (ENST00000313654 LAMA3-B and
ENST00000399516 LAMA3-C) show no difference (Figure 5).
Expression levels of LAMA3 in the Affymetrix sample dataset show
that the low FCs in probesets targeting LAMA3-B and LAMA3-C
are not due to faulty probesets. Thus, there is strong evidence that
LAMA3 is a good candidate for further validation of alternative
splicing. Similar analysis provided additional support for WDR66
(Figure 4C). NRG1 featured 3 probesets, with high absolute
expression and low fold-change, that were subsequently found to
show similar patterns across all samples in the Affymetrix sample
dataset; suggesting that these probesets may be saturating and that
NRG1 may be a false positive (Figure 4D). NDUFA4L2 presents a
similar case to NRG1. COL4A6 is targeted by a large number of
probesets. Theseshow high variation in FC with regionsof similar FC
values. Most probesets are absent in the five low HS samples, making
it unfeasible to infer alternative splicing with respect to HS values,
based on the information available. However, this information
suggests that the possibility of a shorter isoform of COL4A6 being
expressed in high HS values should not be discarded.
Using our pipeline we identified SLCO1B3, WDR66, COL4A6
and LAMA3 as potentially involved in alternative splicing events
associated with hypoxia in HNSCC.
Validation of LAMA3
Laminin a 3( LAMA3) forms the a subunit of laminin-332, an
extracellular glycoprotein, known to be important in cell migration
and tumour invasion [25]. Laminin-332, detected by immunohis-
tochemistry to the gamma 2 subunit, has been found at the
Figure 3. Alternative splicing in the HNSCC dataset. (A) Ranked splicing indices (SI) versus ranked range of fold change values. (B) Ranked SIs
versus ranked VFC values. When the information of the DABGs is incorporated into the range of FCs, through the VFC metric, several genes high-
ranked in (A) fall down the ranking in (B). Genes with bold background were further inspected manually.
doi:10.1371/journal.pcbi.1000571.g003
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PLoS Computational Biology | www.ploscompbiol.org 5 November 2009 | Volume 5 | Issue 11 | e1000571Figure 4. Expression of selected genes in 40 exon arrays. (A) BNC1, (B) SLCO1B3, (C) WDR66 and (D) NRG1 in 40 exon arrays: 10 HNSCC (5 low
HS and 5 high HS) and 10 tissue types in triplicate from Affymetrix. In each figure, the top panel plots the mean expression level for each sample
group (10 tissue types, low HS HNSCC and high HS HNSCC). The central panel plots the fold change value per probeset in the HNSCC dataset. The
horizontal line indicates the FC threshold cut-off at 5% FDR. The bottom panel displays the DABG p-values per sample per probeset: present
(p{valuev0:01) red and absent (p{valuew0:01) blue. The top 30 rows correspond to the 10 tissue types in triplicate, and the bottom 10 to the
HNSCC samples ordered by HS score (low to high - top to bottom).
doi:10.1371/journal.pcbi.1000571.g004
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with a poor prognosis in a wide range of epithelial carcinomas
including oral, cervical and oesophageal cancers [26–28]. LAMA3
is known to be alternatively spliced [29] with the shorter transcript,
Laminin a 3A, encoding the protein subunit for the well
characterised laminin-332.
Clustering and Principal Component Analysis
(PCA). We calculated the Enhanced correlation coefficient
[30] of the set of probesets targeting LAMA3 to all the probesets
targeting (up- and down-regulated) DE genes. Unsupervised
hierarchical clustering of the resulting correlation matrix
separates LAMA3 probesets into LAMA3-A and LAMA3-B
transcripts (Figure S4). Functional annotation analysis using
DAVID [23,24] shows that the probesets with the largest
contribution to the clustering of LAMA3 probesets into the two
distinctive transcripts (based on the first and second components of
the PCA [31] of the correlation matrix, Figure S5 and Table S2),
are significantly enriched (adjusted p-value for multiple testing
v0:05) in genes involved in biological adhesion, immune system
process and cell motility (Table S3).
qRT-PCR. qRT-PCR was carried out on RNA from the 10
original HNSCC tumours. Further RT-PCR experiments were
carried out on cell lines to investigate whether expression of
LAMA3-A could be induced by hypoxia in HNSCC tumour cells.
There was a significant increase in expression of LAMA3-A
between the 5 low and 5 high HS samples (p=0.016), but no
difference in expression of LAMA3-B between the two groups in
the 10 HNSCC clinical samples (Figure 6A). SLC2A1 (Glucose
transporter type 1 (GLUT1), ENSG00000174640) is a HIF{1a
regulated, hypoxia inducible gene known to be expressed in
HNSCC. As expected, the exon array data identified SLC2A1 as
being differentially expressed between the high and low HS groups
but without evidence of alternative splicing. Two distinct sets of
primers to SLC2A1 which targeted different transcripts and
different exons were designed to act as a positive control i.e. to
show increased expression under hypoxia but without differential
expression (Figure 6B). Expression of SLC2A1-A and SLC2A1-B
were both significantly higher in the 5 high HS samples compared
to the 5 low HS samples.
In cell lines, both LAMA3-B and LAMA3-A showed no statistically
significant increases in expression in response to 1% oxygen compared
to atmospheric oxygen (Figure 7A). SLC2A1 expression was
consistently increased in the hypoxic samples for both assays signifying
an appropriate hypoxic response in the cells (Figure 7B).
Figure 5. LAMA3 transcripts, exon distribution and expression. (A) LAMA3 transcripts and exon distribution. Fold changes per exon are
indicated by the colormap. (B) Expression of LAMA3 in 40 exon arrays: 10 HNSCC (5 low HS and 5 high HS) and 10 tissue types in triplicate from
Affymetrix. The top figure plots the mean expression level for each sample group (10 tissue types, low HS HNSCC and high HS HNSCC). The middle
figure plots the fold change value per probeset in the HNSCC dataset. The horizontal line indicates the FC threshold cut-off at 5% FDR. The bottom
figure displays the DABG p-values per sample per probeset: present (p{valuev0:01) red and absent (p{valuew0:01) blue. The top 30 rows
correspond to the 10 tissue types in triplicate, and the bottom 10 to the HNSCC samples ordered by HS score (low to high - top to bottom).
doi:10.1371/journal.pcbi.1000571.g005
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four probesets to LAMA3 (one to transcript LAMA3-A, two to
LAMA3-B and one to LAMA3-B and LAMA3-C), the original
microarray data from the 59 HNSCC patient series were
reanalysed. Outcome data were available for this series of
patients and the LAMA3-A probeset showed expression to be
significantly correlated with overall survival in univariate analysis
(Figure 8A), while LAMA3-B (all probesets) failed to show this
correlation, see Figure 8B. Probesets targeting genes known to be
hypoxia induced, such as CA9, SLCO1B3 and SLC2A1, also failed
to show a correlation with survival.
Materials and Methods
Exon array analysis was performed using the Bioconductor
package Exonmap [7,8], which includes a variety of routines for
translating between probesets, exons, genes and transcripts,
defined by the annotation database X:Map [9].
Head and neck cancer dataset
In [19] 59 Head and Neck Squamous Cell Carcinoma
(HNSCCs) samples, obtained prior to any treatment at the time
of primary surgery, were processed onto Affymetrix HG-U133
Plus2 arrays and a set of 99 genes up-regulated in hypoxia was
obtained by analysis of genes whose in vivo expression clustered
with the expression of 10 well-known hypoxia-regulated genes (e.g.
CA9, GLUT1, and VEGF). A Hypoxia Score (HS) was defined as
the median value of expression for these 99 genes (‘HS genes’).
High HS values indicated higher hypoxia relative to lower values
and were an adverse prognostic factor in an independent
microarray dataset. HS was a continuous variable well spread
across the samples (Figure S6).
Figure 6. LAMA3 in the 10 clinical HNSCC samples. The distribution of gene expression values derived from normalised quantitative RT-PCR Ct
readings. A lower Ct reading indicates higher gene expression. (A) Gene expression values for primers specific to the two transcripts of LAMA3 across
10 clinical HNSCC samples comprising 5 with low HS values (L1 to L5) and 5 with high HS values (H1 to H5). Gene expression values for LAMA3-A are
significantly higher in the high HS samples compared to the low HS samples; p=0.008 (Mann-Whitney U test). There was no significant difference in
expression in LAMA3-B values between high and low HS groups. (B) Gene expression values for primers specific to two distinct regions of SLC2A1.
Both primers show higher expression in high HS samples compared to low HS and there is no significant difference in pattern of expression of
primers within samples.
doi:10.1371/journal.pcbi.1000571.g006
Figure 7. LAMA3 in HNSCC cell lines. Relative gene expression of (A) LAMA3 and (B) SLC2A1 primers showing changes in expression in hypoxia
relative to normoxia in CAL-27 and FaDu cell lines. At least 3 data points were collected for each of 3 independent biological repeat experiments.
doi:10.1371/journal.pcbi.1000571.g007
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percentage of absent calls [32] by removing the top 10-th quantile
of the samples ordered by number of absent calls, and then
selected the 5 least and 5 most hypoxic samples as defined by the
HS values. Confirmation of hypoxia status was carried out by
investigating CAIX protein expression [10] in histological sections.
There was a statistically significant increased CAIX expression in
the samples with high HS values (p=0.024, Figure S7). These 10
samples were then processed onto Affymetrix Human Exon 1.0ST
arrays using manufacturers’ standard protocols, as described in
[7]. Following hybridization, we investigated the similarity in
expression profiles among the 10 exon arrays. Multidimensional
scaling and hierarchical clustering of the samples based on a
reduced set of probesets (exonic probesets flagged present; DABG
p{valuev0:01 in at least half of all the samples; N=172,204)
confirmed that the samples are partitioned by high and low HS
values, as expected (Figure S8). Exon array data have been
deposited in NCBI’s Gene Expression Omnibus [33] and are
accessible through GEO Series accession number GSE18300.
Genes with changes in expression across their loci
Figure 1 shows the analysis pipeline used to identify DE genes in
exon array data. Data were first summarised using RMA [34]
(there is no significant difference between RMA and PLIER in
terms of alternative splicing identification [35]) and then filtered to
include only exon targeting probesets, predicted to hybridize to a
single locus within the genome. A DABG score filtering
(p{valuev0:01 in all samples of at least one replicate set, see
Text S1) and a t-test are then applied to each probeset. Here, we
use the t-statistic for simplicity of implementation; however, any
other suitable test could be used. An FDR[36] of 5% was used as a
cut-off for statistical significance. The starting point for further
analysis is then the set of differentially expressed exonic, non-
multiply targeting probesets that passed the DABG score filtering.
As such, it is similar to the set of DE probesets that would emerge
from a standard analysis of 39IVT arrays.
Two parallel tracks to identify differentially expressed
genes. The availability of multiple probesets per gene can be use
to increase the power of detection of DE genes beyond the
sensitivity of 39IVT arrays, by seeking a series of small but
significant changes in several probesets along the gene. The
alternative scenario in which a single probeset shows a larger
significant change is also of interest (particularly in the context of
alternative splicing).
We seek both types of events thought two parallel procedures
(Figure 1). In Track 1, DE probesets with a FC cut-off defined at the
5% FDR level are selected and mapped to genes. In Track 2 of the
pipeline, DE probesets (PDE) are mapped to genes. These genes are
mapped back to all (4+ probe) exonic probesets (Pe)a n dt h e
proportion of PDE in Pe per gene is calculated. Genes with a
proportion higher than 0.25 (cut-off defined using Bootstrapping; see
Text S2) are selected. The total set of DE genes in the experiment
results from the union of these two tracks of the procedure.
Alternative splicing
Alternative splicing occurs as a result of the differential inclusion
or exclusion of one or more exons from a gene, and can also
involve the retention of intron sequence or the use of alternative 59
and 39 splice sites [37]. In this work we concentrated on events
related to differential exon usage, therefore, introns and intergenic
regions were not considered. We used the combination of two
alternative splicing metrics to identify genes alternatively spliced
with respect to high and low HS values: the splicing index and the
VFC (Variation of reliability weighted Fold Changes). These are
described in detail below.
The splicing index (SI) of probeset p relative to gene g is defined as
SIp~log2
Np1
Np2

, ð1Þ
where Np1 and Np2 are the means of the inclusion rates of probeset p
in gene g across all replicates for sample groups 1 and 2, respectively.
The inclusion rate of probeset p,i ng e n eg,i ng ro u pc,i nr e p l i c a t er is
given by
Npcr~
Pcr
Gcr
ð2Þ
where Pcr is the expression level of probeset p and Gcr is the gene
level of gene g. The gene level can be calculated by taking the mean
Figure 8. Kaplan-Meier plots of LAMA3 expression. Kaplan-Meier plots showing overall survival of 59 HNSCC patients treated with surgery and
appropriate adjuvant treatment. Patients were stratified by RNA expression (highest quartile vs. remaining three quartiles) of (A) LAMA3-A (probeset
203726_s_at) or (B) LAMA3-B (probeset 1563772_a_at).
doi:10.1371/journal.pcbi.1000571.g008
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highly dependent on the gene level calculation, and is reported to
work best when the gene has a large number of constitutive exons and
a small number of alternative exons [38].
To calculate the VFC, the range of FCs for all exonic probesets
across a gene is calculated. The range is used because it is sensitive
to extremes. Alternatives, such as the coefficient of variation or the
standard deviation minimise the effects of these outliers, reducing
the algorithm’s ability to identify single probeset changes. An
obvious problem when using FCs is that each FC has different
degrees of reliability specified by the DABG p-values. To
incorporate this information, we centre the FC values around
the median FC and weight them by the number of samples flagged
present, mapped through a sigmoid transformation. We define the
weight of probeset p as:
Wp~
1
1ze
20 0:75{ nsp=ns ðÞ ðÞ
ð3Þ
where nsp is the number of present samples of probeset p and ns is
the total number of samples. Finally, we normalise the absolute
range of weighted FCs by the weighted-mean of FCs across all
probesets. This normalisation is necessary to eliminate the bias
resulting from the relationship between mean and range of FCs
per gene. A positive correlation is observed because many genes
have at least one probeset whose value is not detectable above
background (high DABG p-value) in most of the samples and has a
reduced difference of the mean value between the two sample
groups (producing low FCs) inducing a large range of FCs across
the gene by lowering the minimum FC value. The VFC of gene g
is thus:
VFCg~
max
np
p~1 FCp{mg

Wp

{min
np
p~1 FCp{mg

Wp
   
  
Mg
ð4Þ
where np is the number of non-multiply targeting exonic probesets
targeting gene g, FCp is the FC of probeset p, and mg and Mg are
the median and weighted-mean of FCs in gene g.
RT-PCR validation
Cell culture. Two head and neck squamous carcinoma cell
lines, FaDu and CAL-27, were obtained from the American Type
Culture Collection (Manassas, VA). Cells were cultured as
recommended by the supplier, in Dulbecco’s modified eagles
media supplemented with L-glutamine (1.5 mM) and fetal bovine
serum (10%). Cells were cultured at 370C in an atmosphere of 5%
CO2 in air.
Hypoxia induction. Cells were plated onto glass plates and
allowed to adhere for 24 hours under normoxic conditions prior to
transferring to a hypoxia cabinet (Fred-Biotrace workstation) and a
media change under hypoxia to hypoxia-equilibrated media.
Hypoxia in this setting refers to 1% oxygen with the remainder
made up of 5% CO2 in nitrogen. Cell were trypsinised and
harvested after 24 hours of exposure using hypoxia-equilibrated
reagents. Cells were also cultured and harvested under normoxic
conditions at the same time points. A minimum of three biological
replicate experiments for each cell line was carried out.
RNA extraction. Total RNA was isolated using RNeasy mini
kit from Qiagen, with an on-column DNase treatment (Qiagen)
according to manufacturer’s instructions. Concentration and
purity of RNA was determined using the NanoDrop
spectrophotometer (NanoDrop Technologies, Wilmington, DE).
Reverse transcription was carried out using the Taqman reverse
transcription reagent kit (Applied Biosystems, Cheshire, UK). One
mg of RNA was incubated with 2:5mM random hexamers,
multiscribe enzyme and other reagents as specified by Applied
Biosystems (part no. 402876, 2002). Reactions were then placed
into a thermocycler (GeneAmp, PCR system 9700) and incubated
at 250C for 10 min, 480C for 30 min and 950C for 5 min. RNA
was extracted from HNSCC samples as described previously [19].
RNA from clinical samples was reverse transcribed using the same
reagents as for cell lines with the exception of using oligo dT
primers instead of random hexamers.
Selection of validation candidate genes. Preference was
given to genes in which exon expression patterns matched that of
known splice variants combined with good probeset reliability.
LAMA3 provided the most consistent evidence of hypoxia induced
alternative splicing and was chosen for validation. Because the two
transcripts of LAMA3 varied only at their 59 end it was not possible
to distinguish them using RT-PCR based methods so quantitative
real time PCR (qRT-PCR) was used. SLC2A1 is a well known
hypoxia induced gene which did not appear to be alternatively
spliced in the exon array data or using RT-PCR analysis (Figure
S9). Primers to the 59 and 39 ends of this gene were designed to act
as control assays.
Primer design. qRT-PCR primers were designed using the
Exiqon universal ProbeLibary systems available at www.roche-
applied-science.com (Roche, Basal, Switzerland). Primer oligo-
nucleotides were obtained from MWG (Ebersberg, Germany).
Primer sequences are shown in Table 3. Primers to endogenous
reference genes were designed using the same system (Figure S10).
Primers were screened for potential single nucleotide poly-
morphisms or pseudogene binding. Satisfactory primer efficiencies
were determined by standard curves of known relative con-
centrations of cell line cDNA.
Real-Time PCR. Expression analysis by qRT-PCR was
carried out using an ABI 7900 sequence detector (ABI
Biosciences, Warrington, UK). qRT-PCR assays were carried
out in 11ml reaction volumes in 384 well plates containing 5gg
cDNA in 5ml, 5 pmol primer oligonucleotide, 5 pmol of
ProbeLibrary probe, and 5:25ml Taqman mastermix (ABI).
Pipetting of 384 well plates was performed using a 5070
epMotion pipetting robot (Eppendorf, Hamburg, Germany).
PCR conditions were standardized with temperatures of 500C
for 2 min, 950C for 10 min, followed by 40 cycles of 600C for
1 min and 950C for 15 s. Threshold cycles were determined
automatically using SDS2.1 software.
Determination of endogenous reference genes. A panel
of 10 reference genes was used, comprising five commonly used
reference genes and five genes identified as being consistently
expressed across the 59-sample microarray dataset. Using
GeNorm software [39] b{Actin and RPL11 were selected as
housekeeper control genes for the cell lines, while GNB2 and
RPL24 were used for the clinical samples. Reference genes were
evaluated on samples from both cell lines cultured in hypoxia and
normoxia. Samples were tested in triplicate and median values
calculated.
Clinical samples. Tumour samples were collected as part of
an ethically approved study from patients undergoing potentially
curative resection of HNSCC in Manchester and Oxford. Sample
processing and RNA extraction has been described previously
[19]. Sample demographics are summarised in Table S4.
Statistical analysis. Clinical RT-PCR data were expressed
as Ct values normalised to the expression of the validated
endogenous reference genes. The difference in expression
between the 5 high HS and 5 low HS samples was calculated
using a Mann-Whitney test based upon the ranking of the median
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values meant that samples were tied, ranking was done according
to the number of technical replicates leading to a determined
value.
Cell line RT-PCR data were analysed according to the DDCt
method. In short, the mean of triplicate measures of each gene
target was normalized using the geomean of the two selected
endogenous reference genes. Relative expression of the normalized
values for hypoxic samples relative to the comparable normoxic
samples were determined and the relative gene expression value
determined using the 2{DDCt method [40].
Discussion
There are several publications showing a good correspondence
between fold change values in the Exon and the 39IVT arrays (e.g.
[2,6,41]). These comparisons are usually done on a reduced set of
genes with overlapping probeset locations. However, these
analyses have not compared the relative ability of the platforms
to detect differential expression in a supervised analysis. In part
this is because the main focus in exon array analysis is the study of
alternative splicing. Our work highlights how the analysis of
differential expression is enhanced by using the probeset
multiplicity offered by exon arrays.
We took a novel approach to the handling of DABG p-values in
the identification of alternative splicing events. Typically, when
filtering is performed at all, probesets absent in more than a
predefined number of samples are filtered out. We retain all exonic
probesets per gene when calculating the alternative splicing metric,
but weight their contribution by the number of present samples.
This approach allows a continuous scoring of the reliability of the
probesets based on the DABG p-values across the samples,
avoiding an abrupt ‘in-or-out’ filtering. We also found that on a
number of occasions, a single probeset was responsible for a gene
being flagged as alternatively spliced, but that on further
investigation, that probeset showed little change across a set of
independent experiments, leading us to conclude that the findings
were likely to be spurious.
We first tested our methodology on a sample dataset for which
predicted alternative splicing events where explored by RT-PCR
and we were able to confirm that the inclusion of probeset
reliability information in the VFC metric enables a better
differentiation between the true and false positives. We then used
the method to analyse our Head and Neck dataset and four
hypoxia-associated alternative spliced candidates were identified
(SLCO1B3, WDR66, COL4A6 and LAMA3). We further analysed
and validated LAMA3, which showed the strongest evidence. The
finding was successfully confirmed by RT-PCR and an informed
re-analysis of the original microarray data allowed probes matched
to the LAMA3 transcripts to be identified and a hypoxia-
associated, splice variant dependent prognostic relationship with
outcome to be determined. Antibodies specific to the different
splice variants of LAMA3 were not available, precluding analysis
of the different LAMA3 transcripts at the protein level, but
identification of the prognostic significance of expression of the
LAMA3-A versus LAMA3-B splice variant illustrates the potential
for alternatively spliced transcripts to act as biomarkers of disease.
The additional information provided by splicing data has the
potential to lead to improved specificity for particular tissues or
conditions, over assays that do not discriminate between splice
variants. This also emphasizes the importance of identifying
specific splice variants when interpreting gene expression data.
Cell line experiments at 1% hypoxia failed to demonstrate
convincing hypoxic induction of LAMA3-A, with only low levels
of hypoxia induced expression seen, despite confirmation of a
transcriptional hypoxic response through SLC2A1 (GLUT1)
expression. Our initial stratification of samples for exon array
analysis was based upon the expression of a gene signature of
hypoxia associated genes; direct measurement of hypoxia in these
tumours in vivo was not performed. Instead, additional confirma-
tion of hypoxia status was carried out by investigating CAIX
protein expression in histological sections. CAIX expression was
indeed elevated in samples with high HS values supporting the use
of the hypoxia associated gene expression score as a surrogate
marker for tumour hypoxia, and supporting the hypothesis that
differential LAMA3-A expression is related to tumour hypoxia. It
may be that greater or more prolonged hypoxia, lower pH or
lower glucose levels are required for LAMA3 induction in cell lines
or that this simply represents differences between cell line
experiments and the situation in tumour. LAMA3 has indepen-
dently been shown to be HIF{1a regulated in human
keratinocyte wound response experiments, using Cobalt Chloride
to induce HIF{1a in this case instead of direct hypoxia exposure,
and to have a hypoxia response element associated with the
promoter for LAMA3-A [42]. This represents the likely mecha-
nism underlying any hypoxia associated differential expression of
this transcript. An earlier study however had shown decreased
laminin-332 expression in human keratinocytes in response to
0.2% or 2% hypoxia exposure [43]. Laminin-332 is known to
interact with several components of the extracellular matrix;
particularly its interaction with Collagen VII has been shown to be
Table 3. Primer sequences for LAMA3 and SLC2A1.
Forward Reverse Transcript Exon UP AL
LAMA3-A TGCAAGCGAG CAAGCCTTTAT ENST00000269217 1–2 #20 74 nt
TTATGTGGAG GATCCCGATA
LAMA3-B CCAGGAATAT GGGAGCAGCA ENST00000313654 20–21 #29 65 nt
GGGTTGCTTG CCAGGTAAT
SLC2A1-A GAGCCCAGCA TGATGACTCCA ENST00000372500 1–2 #52 97 nt
GCAAGAAG GTGTTGTAGCC ENST00000372501
SLC2A1-B GCCAGCCAAA GACTCACACTT ENST00000372501 10 #17 69 nt
GTGACAAGAC GGGAATCAGC ENST00000397019
Primer sequences for LAMA3-A (transcript ENST00000269217), LAMA3-B (transcript ENST00000313654), SLC2A1-A (transcripts ENST00000372500 and
ENST00000372501) and SLC2A1-B (transcripts ENST00000372501 and ENST00000397019). UP=UPL probe and AL=amplicon length.
doi:10.1371/journal.pcbi.1000571.t003
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suggest that LAMA3 induction in HNSCC tumours is influenced
by hypoxia but the lack of expression seen in our HNSCC cell
lines implies that expression may also be dependant upon other
factors found in tissues but not in cell culture. Hypoxia is
inherently associated with treatment resistance and a more
aggressive tumour phenotype [10]. It is possible that LAMA3-A
expression is dependent upon factors related to this relationship
rather than being independently hypoxia inducible. Whilst the
exact pathways involved in the expression of this transcript are
unclear this study emphasizes the importance of identifying
individual transcript expression in future biomarker research.
Supporting Information
Figure S1 Probeset expression in HG-U133A Plus2 arrays and
exon arrays. Genes (probesets) containing a single ‘‘outlier sample’’
tend to be rejected as differentially expressed more often in the
exon arrays than in the HG-U133A Plus2 arrays because the
mean difference tends to be smaller in exon arrays. SLC38A5 and
HSD17B1 as examples of this phenomenon.
Found at: doi:10.1371/journal.pcbi.1000571.s001 (0.30 MB EPS)
Figure S2 ALDOA expression in 10 exon arrayed HNSCC
samples. The top panel shows the mean expression level for each
group (Low and High HS) and ‘‘error bars’’ the maximum and
minimum value for each group. The bottom panel plots the fold
change value per probeset; the significantly differentially expressed
probesets are well below the FC cut-off level (shown by the
horizontal black line), i.e. have low fold changes.
Found at: doi:10.1371/journal.pcbi.1000571.s002 (0.36 MB EPS)
Figure S3 SLCO1B3 exon array information. SLCO1B3, also
known as (OATP8) organic anion-transporting polypeptide 8, has
two known transcripts in the ENSEMBL database: ENST-
00000381545 and ENST00000261196. (A) Gene structure in
terms of transcripts and exons; exons coloured by fold change. (B)
Expression of SLCO1B3 in 40 exon arrays: 10 tissue types in
triplicate from Affymetrix and 10 HNSCC (5 low HS and 5 high
HS). In each panel, the top figure plots the mean expression level
for each sample group (10 tissue types, low HS HNSCC and high
HS HNSCC). The middle figure plots the fold change value per
probeset in the HNSCC dataset. The bottom figure displays the
DABG p-values per sample per probeset: present (DABG,0.01)
red and absent (DABG.0.01) green. The top 30 rows correspond
to the 10 tissue types in triplicate, the bold line separates the
bottom 10 HNSCC samples ordered by HS score (high to low
bottom-top).
Found at: doi:10.1371/journal.pcbi.1000571.s003 (0.05 MB PDF)
Figure S4 Correlation matrix analysis of LAMA3 probesets.
Clustering of the correlation matrix of LAMA3 probesets
(transcripts LAMA3-A and LAMA3-B) versus probesets targeting
(up- an down-regulated) DE genes. Heatmap of correlations
ordered by hierarchical clustering in both dimensions. Horizontal
axis correspond to the probesets targeting DE genes and vertical
axis to the probesets targeting LAMA3 (LAMA3-A and LAMA3-B
transcripts). The top cluster in the vertical axis (left) corresponds to
the probesets targeting LAMA3-B only, while the bottom cluster
corresponds to probesets targeting LAMA3-B and LAMA3-A.
Found at: doi:10.1371/journal.pcbi.1000571.s004 (0.91 MB EPS)
Figure S5 PCA of the correlation matrix of LAMA3 probesets.
First and second component of the PCA of the correlation matrix
of LAMA3 probesets (transcripts LAMA3-A and LAMA3-B)
versus probesets targeting DE genes. LAMA3 probesets separate
well into the two distinct transcripts.
Found at: doi:10.1371/journal.pcbi.1000571.s005 (0.02 MB EPS)
Figure S6 Hypoxia Score (HS) distribution. HS is a continuous
variable well-spread across the samples. The bars represent the HS
values for the 59 HNSCCs (order by increasing HS values).
Found at: doi:10.1371/journal.pcbi.1000571.s006 (0.02 MB EPS)
Figure S7 Confirmation of hypoxia status in the HNSCC
samples was carried out by investigating CAIX protein expression
in histological sections. There was a statistically significant
increased CAIX expression in the samples with high HS values
(p=0.024). Paraffin blocks were unavailable for samples L3 and
H2.
Found at: doi:10.1371/journal.pcbi.1000571.s007 (0.01 MB PDF)
Figure S8 Clustering of the 10 HNSCC exon arrays. Ten
HNSCC samples, five with low (L1, L2, …) and 5 with high (H1,
H2, …) HS values. (a) Multidimensional Scaling (MDS) of the
samples - distances among the samples reflect similarity based on
correlation, (b) Hierarchical clustering of the samples (correlation-
based, complete linkage).
Found at: doi:10.1371/journal.pcbi.1000571.s008 (0.24 MB EPS)
Figure S9 PCR products from RT-PCR of SLC2A1. Gel
showing PCR products from RT-PCR of a long transcript for
SLC2A1, using primers SLC2A1-A forward and SLC2A1-B
reverse (predicted length 1479 bp). No smaller PCR fragments
were seen indicating no alternative splicing in this transcript. An
increase in intensity can be seen in the hypoxic sample showing
hypoxic induction of the gene. Primers for SLC2A1-A and Beta-
Actin were also run as a control.
Found at: doi:10.1371/journal.pcbi.1000571.s009 (0.58 MB EPS)
Figure S10 Primers to endogenous reference genes. M-values
obtained from use of the GeNorm applet. GeNorm assesses the
pair wise distribution of endogenous reference genes, identifying
the pair of genes with the most stable geometric mean (lowest M-
value). (a) To determine endogenous reference genes for cell lines,
cDNA was prepared from both HNSCC cell lines across hypoxic
and normoxic time points using 1% hypoxia. (b) To determine
reference genes for use in clinical samples, cDNA from 40
HNSCC samples were analysed using RT-PCR. All qRT-PCR
assays were carried out using the same method as described in the
main text and were carried out on the same 384 well PCR card.
Genes giving undetermined readings were excluded from analysis.
Found at: doi:10.1371/journal.pcbi.1000571.s010 (0.37 MB EPS)
Table S1 Identified hypoxia associated genes.
Found at: doi:10.1371/journal.pcbi.1000571.s011 (0.27 MB EPS)
Table S2 Genes targeted by probesets with the largest contribu-
tiontotheclusteringofthetranscriptsinthePCA(Figure S5),highly
correlated (top quartile) to the set of probesets targeting LAMA3-A.
Found at: doi:10.1371/journal.pcbi.1000571.s012 (0.28 MB EPS)
Table S3 Lists the biological processes significantly enriched in
the gene list shown in Table S2.
Found at: doi:10.1371/journal.pcbi.1000571.s013 (0.25 MB EPS)
Table S4 Demographics of High HS and Low HS groups.
Found at: doi:10.1371/journal.pcbi.1000571.s014 (0.22 MB EPS)
Text S1 Filtering by DABG scores and Bootstrapping
Found at: doi:10.1371/journal.pcbi.1000571.s015 (0.03 MB PDF)
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